论文部分内容阅读
目的：介绍肺癌患者术中应用榄香烯乳进行冲洗的经验。方法：实验组收集北京胸科医院胸外一科肺癌患者30例对照组选择同期术中未进行榄香烯乳冲洗的肺癌患者105例。患者切除肿瘤后使用金港榄香烯冲洗。
榄香烯乳术中应用对肺癌术后引流量的影响
【摘 要】
：
目的：介绍肺癌患者术中应用榄香烯乳进行冲洗的经验。方法：实验组收集北京胸科医院胸外一科肺癌患者30例对照组选择同期术中未进行榄香烯乳冲洗的肺癌患者105例。患者切除肿瘤后使用金港榄香烯冲洗。
【机 构】
：
北京 首都医科大学附属北京胸科医院胸外科
【出 处】
：
第十八届全国临床肿瘤学大会暨2015年CSCO学术年会
【发表日期】
：
2015年4期
其他文献
目的：探讨埃克替尼靶向治疗期间适时手术干预治疗非小细胞肺癌的可行性。方法：对我科经埃克替尼靶向治疗后在不同时机采取手术干预的10例患者进行回顾性分析。结果：10例患者经埃克替尼靶向治疗后均施行手术干预治疗，其中行左全肺切除1例，肺叶切除6例，局部切除3例。
目的：在既往报道中，典型的剂量-体积直方图(DVH)参数是肺癌患者放射治疗后发生放射性肺炎(RP)的预测因素。然而，上述剂量学因素和RP这二者相关的讨论仅在局限的治疗环境中。因此，在本文中我们回顾性评估了DVH对术后放射治疗(PORT)后的肺癌患者发生急性重度放射性肺炎(ASRP)可能存在的预测作用。
High expression of PKM2 is associated with good sensitivity to epirubicin and 5-fluorouracil in brea
Objective: Pyruvatekinase M2 (PKM2) is the key enzyme in Warburg effect and was reported to be involved in metabolic pathways of tumor cells response to chemotherapeutic drugs recently.
Objective: Photothermal therapy (PTT) has emerge as a promising way to treat cancer with minimal invasion and high selectivity.The purpose of this study was to synthesis gold nanoprisms (GNPs) as a ne
A prognostic analysis of male breast cancer (MBC)comparing with post-menopausal female breast cancer
Objective: It is a widely known fact that male breast cancer(MBC) is a rare disease compared with female breast cancer (FBC) and account for only 1% of all breast cancers.
目的： Sirt7,as one of the seven Sirtuin family members,which plays distinct roles in cancer progression,is bringing emerging attention due to its oncogenic characteristic.
SHP-1 Acts as a Tumor Suppressor by Interacting with EGFR and Predicts the Prognosis of Human Breast
目的： Toexamine the prognostic significance of SHP-1 in breast cancer, its role in regulationofbreast cancer cell growth and metastasis, and the underlying mechanisms.
A Case report of response to crizotinib in a squamous cell lung carcinoma patient harbouring EML4-AL
目的： We present a case of ALK gene translocation-squamous cell lung cancer which experienced a remarkable tumor response to crizotinib after failure of prior chemoradiotherapy.
目的：探讨在65例高龄晚期非小细胞肺癌患者中埃克替尼的疗效和安全性。方法：经病理学或细胞学证实≥75岁的ⅢB-Ⅳ期非小细胞肺癌患者，口服埃克替尼125mg每天3次，直至疾病进展或者出现严重不良反应，评价疗效及不良反应。
目的：Ⅲ期临床试验(ICOGEN)显示，埃克替尼在ⅢB/Ⅳ期非小细胞肺癌亚洲人群的安全性和有效性不劣于吉非替尼。本项回顾性研究目的为评估埃克替尼在EGFR状态未知且首月试用有效人群和EGFR敏感突变(19外显子缺失、21号外显子L858R突变)人群的有效性和安全性。